Anaptys Announces Participation in Upcoming Investor Conferences
SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:
UBS Global Biopharma Conference 2026, London
- Format – Fireside chat
- Date and Time – Tuesday, November 17, 2026 at 4:40pm GMT / 11:40am ET
- Participant – Daniel Faga, president and chief executive officer
Piper Sandler 38th Annual Healthcare Conference, New York
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Wednesday, December 2, 2026 at 8:00am ET
- Participant – Chris Murphy, chief financial officer
9th Annual Evercore Healthcare Conference, Miami
- Format – Fireside chat
- Date and Time – Wednesday, December 2, 2026 at 10:50am ET
- Participant – Daniel Faga, president and chief executive officer
Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presentations-and-events. Replays of the webcasts will be available for at least 30 days following the events.
About Anaptys
Anaptys manages the financial collaborations for Jemperli with GSK and Quimilza with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Contact:
Chris Murphy
Chief Financial Officer
investors@anaptysbio.com